Board of Directors
Our Board of Directors come from a wide-range of backgrounds to enable us to access a broad knowledge base.
Garry Watts, FCA, MBE joined the Board a Chairman in January 2012. He is Chairman of the Nomination Committee.
Other directorships: Garry is Chairman of Spire Healthcare and of Foxtons Group plc. and is a non-executive director of Coca-Cola Enterprises, Inc.
Expertise and experience: Garry provides considerable commercial leadership experience and expertise to the BTG Board. For seven years up to December 2010, he was CEO of SSL International plc and before that its CFO. He was previously an executive director of Celltech plc and of Medeva plc, and a non-executive director of Protherics PLC and of Stagecoach Group plc. Other roles have included 17 years as a member of the UK Medicines and Healthcare Products Regulatory Agency Supervisory Board. Garry is a former partner at KPMG.
Dame Louise Makin
Chief Executive Officer
Dame Louise Makin MA, PhD (Cantab), MBA, DBE joined BTG as Chief Executive Officer in October 2004.
Other directorships: Louise is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust. She is a Trustee of the Outward Bound Trust, Chair of the 1851 Trust, an Honorary Fellow of St. John’s College, Cambridge and a member of the 30% Club.
Expertise and experience: Louise is a highly experienced international business leader, who brings considerable strategic and operational expertise to the Board. Prior to joining BTG she was from 2001, President, Biopharmaceuticals Europe of Baxter Healthcare, with responsibility for Europe, Africa and the Middle East. Before Baxter, Louise was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles during 13 years at ICI.
Chief Financial Officer
Duncan Kennedy joined the Board as Chief Financial Officer in January 2018.
Other directorships: Duncan currently holds no external directorships.
Expertise and experience: Duncan provides significant financial expertise to the Board. Before being appointed CFO, Duncan led BTG’s Interventional Oncology business, a role he has held since May 2015. Duncan joined BTG in December 2005 as Group Financial Controller and became a member of the Leadership Team in April 2012 when he was appointed Group Director of Finance, with responsibility for managing the global finance function and supporting the CFO. Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.
Gregory Barrett was appointed to the Board in January 2018.
Other directorships: Gregory is currently a non-executive director of Cutera Inc. and currently sits on the Board of Aqua Medical. Past Board positions include Chairman roles at Monteris Medical and Barrx Inc.
Expertise and experience: Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery divisions of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.
Dr. Susan Foden
Dr. Susan Foden, MA, DPhil was appointed to the Board March 2015. She is a member of the Remuneration Committee.
Other directorships: Susan currently holds non-executive roles with BerGenBio ASA, Evgen Pharma plc and Vectura Group plc, and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund).
Expertise and experience: Susan brings extensive industry experience to the BTG Board with a strong track record of having assisted in the development of a number of businesses in the sector. She was Investor Director with the venture capital firm Merlin Biosciences, was formerly CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and was Head of Academic Liaison at Celltech Ltd.
Graham Hetherington was appointed to the Board in August 2016. He is the Company’s Senior Independent Director and is Chairman of the Audit Committee and a member of the Remuneration Committee
Other directorships: Graham currently holds no other directorships.
Expertise and experience: Graham brings substantial financial and industry experience to the BTG Board. Prior to joining BTG he was Chief Financial Officer of Shire plc, a role he held from June 2008 to February 2014. Previously he held the same positions at Bacardi in 2007 and at Allied Domecq PLC from 1999 to 2005. Graham has a broad knowledge of international finance management and planning, including M&A, audit and risk management and is a Fellow of the Chartered Institute of Management Accountants.
Giles Kerr, FCA was appointed to the Board in October 2007. He is a member of the Audit, Nomination and Remuneration Committees.
Other directorships: Giles is the Director of Finance with the University of Oxford, UK. He is also a Director of Oxford University Innovation Ltd, Senior plc, PayPoint plc, and Adaptimmune Therapeutics plc and is non-executive Director and Chair of the Audit Committee at Arix Bioscience plc.
Expertise and experience: Giles provides important relevant industry and financial experience to the BTG Board. He was previously the Group Finance Director and Chief Financial Officer of Amersham plc, acquired by GE Healthcare in 2004, and previously served as Director of Victrex plc. Prior to his role at Amersham, he was a partner with Arthur Andersen in the UK. He was Chairman of the Company’s Audit Committee until the appointment of Graham Hetherington.
Ian Much was appointed to the Board in August 2010. He is Chairman of the Remuneration Committee and a member of the Audit and Nominations Committees.
Other directorships: Ian currently holds no other directorships.
Expertise and experience: Ian provides substantial international business experience to the Board. He was Chief Executive of De La Rue plc between 1998 and 2004 and Chief Executive of T&N plc between 1996 and 1998. Previously he was non-executive director of Manchester United plc, Camelot plc, Admiral plc, and Chemring Group plc.
Jim O’Shea was appointed to the Board in April 2009. He is a member of the Nomination Committee.
Other directorships: Jim serves as Chairman of Cardiome Pharma, is a director of Trevi Therapeutics, Inc., and Ocular Therapeutix™.
Expertise and experience: Jim provides the Board with significant US Industry experience. He is a former Chairman of the US National Pharmaceuticals Council. From 2007 to 2008, he was Vice Chairman of Sepracor, Inc., where he was also President and Chief Operating Officer from 1999 to 2007. Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals (US), a business unit of Zeneca Inc. While at Zeneca, he held several management positions of increasing responsibility in international sales and marketing in the US and the UK.
Anne Thornburn was appointed to the Board in January 2018. She is a member of the Audit Committee.
Other directorships: Anne is non-executive director and Chair of the Audit Committee of Diploma PLC.
Expertise and experience: Anne has an extensive range of international financial management, risk, audit and M&A experience. She was Chief Financial Officer of Exova Group plc from 2009 to 2015 and previously served as Group Finance Director at British Polythene Industries PLC. Anne is a member of the Institute of Chartered Accountants in Scotland
Richard Wohanka was appointed to the Board in January 2013. He is a member of the Audit Committee.
Other directorships: Richard is a board member of Lloyds Banking Group Insurance (Scottish Widows), Julius Baer International Limited and Chairman of the Nuclear Liabilities Fund and of Old Mutual Global Investors.
Expertise and experience: Richard provides substantial expertise to the BTG Board in the field of business and finance, with more than twenty years' experience in building asset management businesses. He was CEO of Union Bancaire Privée Asset Management between October 2009 and June 2012, and from 2001 to 2009 he was CEO of Fortis Investment Management.
We have a rich heritage. Learn about our transformation from commercialisation of intellectual property to medical technology used in minimally invasive procedures.Read more
Our Code of Conduct has been developed to promote ethical behaviour from all our employees and is based on our foundation of core company values.Read more